1021912-99-1

Basic information

• Product Name: diethyl {[(3-chloro-4-iodophenyl)amino]methylidene}propanedioate
• Synonyms: diethyl {[(3-chloro-4-iodophenyl)amino]methylidene}propanedioate
• CAS NO: 1021912-99-1
• Molecular Weight: 423.635
• Mol File: 1021912-99-1.mol

Chemical Properties

• CAS DataBase Reference: diethyl {[(3-chloro-4-iodophenyl)amino]methylidene}propanedioate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl {[(3-chloro-4-iodophenyl)amino]methylidene}propanedioate(1021912-99-1)
• EPA Substance Registry System: diethyl {[(3-chloro-4-iodophenyl)amino]methylidene}propanedioate(1021912-99-1)

Safety Data

• Hazardous Substances Data: 1021912-99-1(Hazardous Substances Data)

Upstream product

• 135050-44-1 3-chloro-4-iodoaniline 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 

Downstream Products

• 1021913-01-8 ethyl 7-chloro-4-hydroxy-6-iodoquinoline-3-carboxylate 
• 1021912-69-5 5-[7-chloro-3-(3,5-dimethylphenyl)-4-{2-[(2R)-piperidin-2-yl]ethoxy}quinolin-6-yl]pyridin-2(1H)-one 
• 1276063-77-4 7-chloro-3-(3,5-dimethylphenyl)-4-{2-[(2R)-piperidin-2-yl]ethoxy}-6-(pyridin-3-yl)quinoline 
• 1032816-26-4 C₃₆H₄₀ClN₃O₄ 

Relevant articles and documents

AMINO-QUINOLINES AS KINASE INHIBITORS

Disclosed are compounds having the formula:wherein R 1 , R 2 , R 3 and Z are as defined herein, and methods of making and using the same.

AMINO-QUINOLINES AS KINASE INHIBITORS

Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.

AMINO-QUINOLINES AS KINASE INHIBITORS

Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.

COMBINATION THERAPIES FOR TREATMENT OF CANCER

Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

INHIBITORS OF KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Design, synthesis, and evaluation of novel 3,6-diaryl-4- aminoalkoxyquinolines as selective agonists of somatostatin receptor subtype 2

Agonists of somatostatin receptor subtype 2 (sst2) have been proposed as therapeutics for the treatment of proliferative diabetic retinopathy and exudative age-related macular degeneration. An HTS screen identified 2-quinolones as weak agonists of sst2, and these were optimized to provide small molecules with sst2 binding and functional potency comparable to peptide agonists. Agonist 21 was shown to inhibit rat growth hormone secretion following systemic administration and to inhibit ocular neovascular lesion formation after local administration.

Controlled derivatization of polyhalogenated quinolines utilizing selective cross-coupling reactions

Straightforward procedures for the derivatization of tri- and tetrahalogenated quinolines utilizing sequential selective Pd-catalyzed cross-coupling reactions are described. Taking advantage of intrinsic halide reactivity, substrate control, and appropria

SOMATOSTATIN AGONISTS

This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy,